Investors & Media
News
Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting
Below is the schedule for the poster presentations:
Date: |
|
|||
Poster Presentation Time: |
|
|||
Location: |
|
|||
Poster Number: |
10 | |||
Title: |
Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super-Refractory Status Epilepticus | |||
Date: |
|
|||
Poster Presentation Time: |
|
|||
Location: |
|
|||
Poster Number: |
168 | |||
Title: |
Pharmacokinetics of SAGE-547 in Patients with Super-Refractory Status Epilepticus | |||
Date: |
|
|||
Poster Presentation Time: |
|
|||
Location: |
|
|||
Poster Number: |
172 | |||
Title: |
SAGE-547 (allopregnanolone injection) for the Treatment of Super-Refractory Status Epilepticus: Response and Relationship to Underlying Patient Characteristics | |||
Date: |
|
|||
Poster Presentation Time: |
|
|||
Location: |
|
|||
Poster Number: |
174 | |||
Title: |
Phase 1/2 Open-Label Data Suggest that Heterogeneity of Presentation and High Burden of Comorbid Illness Do Not Impact the Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus | |||
Date: |
|
|||
Poster Presentation Time: |
|
|||
Location: |
|
|||
Poster Number: |
165 | |||
Title: |
|
|||
In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:
Date: |
|
|||
Time: |
|
|||
Location: |
|
|||
Title: |
Diagnosis and Management of Super-Refractory Status Epilepticus | |||
About
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005142/en/
Investors:
paul.cox@sagerx.com
or
Media:
maureen.suda@sagerx.com
Source:
News Provided by Acquire Media